Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
301 Leser
Artikel bewerten:
(1)

BioCatch, the Leading Online Fraud Detection Platform, welcomes Permira Growth Opportunities as a significant shareholder

Finanznachrichten News

Secondary investment positions Permira Growth Opportunities (PGO) as 3rd largest BioCatch shareholder; creates opportunities for accelerated geographical expansion, product innovation, and M&A

NEW YORK and TEL AVIV, Israel, May 3, 2023 /PRNewswire/ -- BioCatch, the pioneer of behavioral biometrics intelligence and a global leader in digital fraud detection, today announced that Permira Growth Opportunities has acquired a significant minority stake in the company from existing investors, making it the third largest shareholder in the company, following Bain Capital and Maverick Capital. With the support of its shareholders, BioCatch will focus on accelerating opportunities for geographical expansion, product innovation, and potential M&A.

BioCatch is the leader in Behavioral Biometrics, a technology that leverages machine learning to analyze an online user's physical and cognitive digital behavior to protect individuals online.

BioCatch is the leader in behavioral biometric intelligence and advanced digital fraud detection, leveraging technology built upon patented artificial intelligence and machine learning technology to collect thousands of data signals, analyze a user's cognitive intent, and deliver highly accurate insights as to the legitimacy of their identity and behavior. Today, BioCatch counts over 100 leading global banks as customers, including over 25 of the top 100 global banks, who use BioCatch solutions to fight fraud, accelerate digital transformation, create new revenue channels, and improve customer satisfaction.

"We are excited to welcome Permira as our partner and look forward to working together to further expand our leadership position in the digital fraud prevention sector. Permira is one of the leading global private equity firms in the world, with particularly strong experience in the technology space, and we believe its deep sector expertise and company-building capabilities will help us to expand our business and strengthen our global position," said Gadi Mazor, CEO of BioCatch.

"Through our focus on the online fraud detection, customer identity and access management markets, we have long admired BioCatch and have been impressed by the company's performance and offering. We believe BioCatch is well-positioned to continue to gain market share and expand its leading position within the large, growing area of online fraud detection," said Stefan Dziarski, Partner and member of the PGO investment committee.

"We look to back product-first businesses operating in structurally growing end markets and that have management teams with the ambition to scale and grow their business. We found all of that in BioCatch and believe it is the clear leader in the most critical layer in online fraud detection - behavioral biometrics. We look forward to supporting BioCatch in its next phase of growth," added Ran Maidan, Senior Adviser and Head of Permira in Israel.

About BioCatch

BioCatch is the pioneer of behavioral biometric intelligence and a global leader in advanced fraud detection. BioCatch's mission is to unlock the power of behavior and deliver actionable insights to create a digital world where identity, trust and ease seamlessly co-exist. Today, over 100 global banks leverage BioCatch solutions to fight fraud and transform their customers' digital experience. BioCatch's Client Innovation Board, an industry-led initiative including American Express, Barclays, Citi Ventures, and National Australia Bank, helps enable BioCatch to identify creative and cutting-edge ways to leverage the unique attributes of behavior for fraud prevention. With over a decade of analyzing data, more than 80 registered patents, and unparalleled research into human behavior, BioCatch continues to innovate to solve tomorrow's digital problems.

About Permira

Permira is a global investment firm that backs successful businesses with growth ambitions. Founded in 1985, the firm advises funds with total committed capital of approximately €77bn and makes long-term majority and minority investments across two core asset classes, private equity and credit.

The Permira funds have an extensive track record in technology investing, having invested in 50+ companies across SaaS, cybersecurity, digital commerce, fintech and online marketplaces. Permira invested in BioCatch via its Growth Opportunities Fund; its strategy is to back disruptive technology and tech-enabled companies as they scale to the next level. The Permira funds have previously supported and helped scale some of the largest and fastest-growing technology businesses globally, including Genesys, TeamViewer, Zendesk, McAfee, Mimecast, Carta, G2, Sysdig, SonarSource, Mirakl, and others. Permira closed its second Growth Opportunities Fund in December 2021 at $4 billion.

The Permira private equity funds have made approximately 300 private equity investments in four key sectors: Technology, Consumer, Healthcare and Services. Permira employs over 470 people in 15 offices across Europe, the United States and Asia. For more information, visit www.permira.com or follow us on LinkedIn or Twitter.

Media Contacts

For BioCatch

Hugh James
hugh.james@teamlewis.com

For Permira

Nina Suter
Nina.Suter@permira.com
+44 207 9594037

James Williams
james.williams@permira.com
+44 774 7006407

Logo - https://mma.prnewswire.com/media/1843699/biocatch_logo_rgb_2x_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biocatch-the-leading-online-fraud-detection-platform-welcomes-permira-growth-opportunities-as-a-significant-shareholder-301814776.html

© 2023 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.